GlassScriptPhysician profile
Lauren Nueske
NPI 1003492059
$3,777.35
in general payments reported to CMS, 2019-2025
28 companies · $686 in 2025
The $686 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $1,091 · 2023: $749 · 2024: $984 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,392 · Education: $27.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,391.63 |
| Education | $27.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,352.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.98 | 2022-2024 | Xifaxan, Plenvu |
| Phathom Pharmaceuticals, INC. | $304.46 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $192.64 | 2022-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $161.63 | 2021-2022 | |
| Enterra Medical, INC. | $159.04 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $148.58 | 2022-2024 | Dupixent |
| Genzyme Corporation | $122.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.88 | 2022-2024 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $94.26 | 2021-2023 | Suflave, Sutab |
| Celltrion USA INC. | $86.49 | 2024-2025 | Vegzelma, Zymfentra, Yuflyma |
| Aimmune Therapeutics, INC. | $76.63 | 2025 | Zenpep |
| Celgene Corporation | $75.42 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $75.39 | 2025 | Iqirvo |
| Lilly USA, LLC | $64.47 | 2024 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $45.45 | 2022-2023 | Interstim |
| Merck Sharp & Dohme LLC | $43.91 | 2021-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $41.18 | 2022-2025 | Ocaliva |
| Pfizer INC. | $34.94 | 2022 | |
| Ironwood Pharmaceuticals, INC | $32.49 | 2021-2022 | |
| Amgen INC. | $24.54 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $23.31 | 2022 | |
| Ardelyx, INC. | $22.26 | 2025 | Ibsrela |
| Baxter Healthcare | $20.65 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Madrigal Pharmaceuticals | $17.43 | 2025 | Rezdiffra |
| Qol Medical, LLC | $14.02 | 2024 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.89 | 2023 | Cyltezo |
| Gilead Sciences, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Nueske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.